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SUMMARY
Objective: Prevalence of chronic complications of HIV infection is increasing and early recognition and 
treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and 
metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and 
risk-factors for MS among HIV-infected subjects. Methods: A total of 819 patients followed at a large 
outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several 
demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied 
on agreement between patient’s self-report and physician’s observation of altered body-fat deposits. The 
presence of three or more of the following characteristics identified MS: increased waist circumference, 
hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic re-
gression analyses to study variables independently associated with MS. Results: The prevalence of MS 
was 20.6% and that of lipodystrophy was 38.5%. 61 (36.1%) out of 169 patients with MS had also lipo-
dystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had 
higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer expo-
sure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. Conclusion: Both 
traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as 
an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with 
metabolic syndrome in the present study population.
Keywords: Metabolic syndrome X; antiretroviral therapy, highly active; HIV-associated lipodystrophy 
syndrome; HIV; risk factors; cross-sectional studies
RESUMO
O que devemos saber sobre síndrome metabólica e lipodistroﬁa  
na AIDS?
Objetivo: A prevalência de complicações crônicas da infecção HIV está aumentando, e o reconhecimento 
precoce e o tratamento dos componentes da síndrome metabólica (SM) são essenciais para a prevenção 
de complicações cardiovasculares e metabólicas. Considerando isso, realizamos um estudo transversal 
sobre prevalência e fatores de risco para SM em indivíduos HIV+. Métodos: Um total de 819 pacientes 
acompanhados em um ambulatório de HIV foi avaliado por um entrevistador que registrou em ques-
tionário dados demográficos, epidemiológicos, clínicos, laboratoriais e variáveis sociais. O diagnóstico 
de lipodistrofia baseou-se na concordância entre autorrelato do paciente e observação do médico das 
alterações de gordura corporal. A SM foi identificada pela presença de três ou mais das seguintes caracte-
rísticas: circunferência abdominal aumentada, hipertrigliceridemia, colesterol HDL baixo, hipertensão e 
hiperglicemia. Análises de regressão logística foram utilizadas para identificar variáveis associadas à SM. 
Resultados: A prevalência de SM foi 20,6% e de lipodistrofia foi 38,5%. Entre os 169 pacientes com 
SM, 61 (36,1%) apresentavam lipodistrofia. Os pacientes com síndrome metabólica tinham, significati-
vamente, maior probabilidade de ser mais velhos (OR = 1,08), ter maior contagem de CD4 (OR = 1,001), 
ter maior índice de massa corporal (OR = 1,27) e ter maior tempo de exposição à terapia antirretroviral 
(OR = 1,01). Conclusão: Tanto fatores de risco tradicionais para doença cardiovascular quanto fatores 
associados à infecção HIV, como aumento da contagem de CD4 e maior exposição à terapia antirretrovi-
ral, parecem estar associados à SM na população estudada. 
Unitermos: Fatores de risco; síndrome de lipodistrofia associada ao HIV; terapia antirretroviral de alta 
atividade; HIV; síndrome x metabólica; estudos transversais.
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INTRODUCTION
Increased survival experienced by HIV-infected patients 
after the advent of highly active antiretroviral therapy 
(HAART) has been followed by the frequent occurrence 
of chronic metabolic abnormalities, such as dyslipid-
emia, the metabolic syndrome (MS), and HIV-related 
lipodystrophy (LD-HIV)1,2. 
MS is defined as the presence of abdominal obesity, 
insulin resistance, hypertension, and dyslipidemia3. It is 
highly prevalent in both general and HIV-infected popu-
lations4. MS is strongly associated with the development 
of type 2 diabetes mellitus and coronary atherosclero-
sis. MS is associated with the current obesity epidemic 
– more than 1 billion adults are overweight and at least 
300 million of them are clinically obese5. Data from the 
World Health Organization show that in Brazil 54% of 
males and 60% of females over 15 years are overweight 
or obese5. These figures reflect the profound changes 
in alimentary and in behavioral patterns over recent 
decades, with increased consumption of more energy-
dense, nutrient-poor foods with high levels of sugar and 
saturated fats, combined with reduced physical activity6.
LD-HIV can be disfiguring cosmetically, and the 
physical findings may stigmatize the individual as 
one living with HIV infection, a worrisome complica-
tion due to its negative psychological impact on mood, 
self-esteem and, possibly, on adherence to treatment7. 
LD-HIV is composed of three patterns of an altered body 
fat redistribution as follows: lipoatrophy, lipohyperthro-
phy, and simultaneous development of lipoatrophy and 
lipohyperthrophy1,8. These syndromes of fat redistribu-
tion may or may not be associated with dyslipidemia and 
insulin resistance. Its onset may be related to the pro-
gression of HIV infection itself, to host-related factors 
and to the exposure to different antiretroviral agents9.
MS pathogenesis emerges from fat deposition, espe-
cially in the visceral-abdominal region. Its pathogenesis 
is more comprehensive considering the concept of ec-
topic fat deposition, especially in liver and muscle, with 
consequent reduction in insulin sensitivity. Fat deposit 
in organs like liver and muscle has an important role in 
determining insulin resistance. The lack of peripheral 
fat tissue, as occurs in lipodystrophy, would lead to ex-
cessive fat storage in liver and muscle9,10. As the preva-
lence of chronic metabolic disorders is increasing on 
HIV-infected population, and since the early recogni-
tion and treatment of MS are essential to the preven-
tion of its complications, we performed a cross-sectional 
study on the prevalence and risk-factors for MS, and its 
association with LD-HIV, among HIV-infected patients 
followed at a large outpatient HIV unit in Rio de Janeiro, 
Brazil.
METHODS
All HIV-infected patients enrolled in the study were se-
quentially recruited between January and May 2005, as 
of their scheduled visit to the Immunology Laboratory 
at Hospital Universitário Gaffrée e Guinle to perform 
routine CD4 cell count and plasma HIV viral load mea-
surements, as requested by their attending physicians. 
Patients were eligible if they were aged ≥ 18 years and 
were under regular follow-up in the outpatient unit. Ex-
clusion criteria were: pregnancy, lower extremity edema, 
ascites and psychiatric disorder which hinder the pa-
tients’ self-assessment of the body shape. Patients were 
invited to participate in the study after an oral expla-
nation of its objectives and methods and those willing 
to take part were asked to provide a signed informed 
consent. The study protocol was reviewed and approved 
by the Ethics Review Board at Hospital Universitário 
Gaffrée e Guinle and there were no external funding 
sources for this study.
LD-HIV diagnosis relied on agreement between the 
patient’s self-report questionnaire and physician’s exam-
ination of the following altered body areas: the presence 
of peripheral fat wasting with loss of subcutaneous tis-
sue in either the face (temporal and maxillary wasting), 
arms, legs and/or buttocks, classified as lipoatrophy; the 
presence of either enlargement of dorsocervical fat pad 
(“buffalo hump”), circumferential expansion of the neck, 
breast enlargement or abdominal visceral fat accumula-
tion, classified as lipohyperthrophy; or a combination of 
both lipoatrophy and lipohyperthrophy features, classi-
fied as mixed lipodystrophy11.  
The diagnosis of LD-HIV relied on the presence of 
at least one readily noticeable sign in tandem with an-
other mild sign of the altered body fat compartment as 
mentioned before, the agreement between physician’s 
and participants’ self-report evaluations concerning the 
body fat compartments examined, and the absence of 
any signs of AIDS defining illnesses in the 30 days before 
their appointments. Increased abdominal girth was con-
sidered as a valid sign of altered body fat compartment.
MS was identified according to National Cholesterol 
Education Program-Adult Treatment Panel III (NCEP) 
criteria by the presence of three or more of the follow-
ing: waist circumference greater than 102 cm in men and 
88 cm in women; triglycerides ≥ 150 mg/dL; HDL cho-
lesterol < 40 mg/dL (men) and < 50 g/dL (women); arte-
rial blood tension ≥ 130/85 mmHg and fasting glucose 
≥ 110 mg/dL12.
Differences between categorical and continuous [ex-
pressed as mean ± standard deviation (SD)] variables 
were compared by applying the chi-square (χ2) test and 
Student’s t-test, respectively. Statistical significance was 
DARIO JOSE HART PONTES SIGNORINI ET AL.
72 Rev Assoc Med Bras 2012; 58(1):70-75
determined as a p-value of < 0.05. A logistic regression 
analysis was also used to identify variables independent-
ly associated with MS. Age, sex, body mass index (BMI), 
smoking, alcohol consumption, CD4 cell count, expo-
sure and duration of antiretroviral therapy, use of a pro-
tease inhibitor, plasma HIV viral load, and lipodystro-
phy were used as explanatory variables. Those found to 
have a p-value < 0.20 were included in the multivariate 
model. Hosmer-Lemeshow tests were performed to as-
sess the goodness-of-ﬁt of the logistic regression model. 
Odds ratio (OR) and 95% conﬁdence intervals (95% CI) 
were reported along with p-values. The null hypothesis 
was rejected in each statistical test when p-value was 
< 0.05. Statistical analyses were performed by using the 
free software R, version 2.9.113.
RESULTS
A total of 819 patients were included in the study. Among 
these, 447 (54.6%) were male and 372 (45.4%) were fe-
male, with a mean (±  SD) age of 41 (±  11) years (range 
18-75) and a mean BMI of 24 (± 4.4) kg/m2 (range 14-49). 
The vast majority (n = 767, 93.6%) of patients attributed the 
acquisition of HIV infection to unprotected sexual inter-
course. The remaining patients imputed HIV infection to 
blood transfusion or blood products (n  =  35, 4.3%) and 
to intravenous drug use (n = 10, 1.2%). Seven (0.9%) pa-
tients considered that the infection route was indetermi-
nate. Table 1 shows the distribution of demographic, epi-
demiological, clinical and social variables. 
More than two-thirds (n  =  623, 76.1%) of the pa-
tients were receiving HAART, with a mean duration of 
therapy of 54 (± 36) months (range 1-158). Patients on 
treatment were currently receiving two nucleoside re-
verse transcriptase inhibitors as a treatment backbone in 
combination with either one or two protease inhibitors 
(n  =  226, 27.6%) or one non-nucleoside reverse tran-
scriptase inhibitor (n = 397, 48.5%). Most of the treated 
patients (n = 487, 90%) reported a good compliance to 
the HAART regimen (Table 1).
However, a total of 198 (24.2%) patients on more 
than 12 months of treatment had a plasma HIV viral 
load above 100 copies/mL. Patients with longer treat-
ment histories were more likely to have a viral load above 
detection limits. A quarter (n = 215, 26.2%) of these pa-
tients also presented comorbidities such as hypertension 
(16.7%), other cardiovascular diseases (5.6%), and dia-
betes mellitus (3.9%). A family history of diabetes and 
cardiovascular disease was recorded from 38% and 55%, 
respectively.
The prevalence of MS was 20.6% (n = 169) and that 
of LD-HIV was 38.5% (n = 280 out of 721). Sixty-one pa-
tients were found to have both MS and LD-HIV. A total 
of 704 out of 819 (86%) patients had at least one com-
ponent of MS. A low HDL-cholesterol level (91%) was 
the most prevalent component of diagnostic criteria for 
MS followed by hypertriglyceridemia (87.1%), increased 
blood pressure (78.8%), increased waist circumference 
(42.2%) and hyperglycemia (31.8%).
In a subgroup of 623 patients receiving HAART, pa-
tients with MS were more likely to be older, fatter, had a 
longer exposure to antiretroviral therapy and had greater 
CD4 cell counts than those without MS. There was no 
difference in the mean BMI (both groups ≈  24 kg/m2, 
t-test = 0.66, p-value = 0.51) and plasma HIV viral load 
(t-test = 0.86, p-value = 0.40) between these groups. None-
theless, patients with MS were less likely to be adherent to 
the treatment (chi-square = 3.98, p < 0.05) (Table 2).
We were able to screen a total of 721 patients for phys-
ical signs of LD-HIV and found a prevalence of 38.5% 
(280). LD-HIV and MS were not statistically associated 
in this study (chi-square test  =  0.94; p-value  =  0.33), 
Variables N
Male gender, n (%) 447 (54.6)
Age (mean [±SD]) years 41 (±11)
Schooling (n = 819)  
≥ 8 years of schooling, n (%) 541 (66)
< 8 years of schooling, n (%) 278 (34)
Smoking, n (%) 213 (26)
Alcohol consumption, n (%) 294 (35.9)
Illicit drug use (n = 819), n (%) 48 (5.9)
Former consumer*, n (%) 102 (12.5)
Regular physical activity, n (%) 188 (23)
HIV acquisition route  
Sexual intercourse, n (%) 770 (93.6)
Blood transfusion, n (%) 35 (4.3)
Intravenous drug use, n (%) 10 (1.2)
Not determinate, n (%) 7 (0.9)
Absolute CD4 cell count, cells/mm3 (±SD) 394 (±245)
Current antiretroviral regimen (n = 623)  
NRTIs plus PI, n (%) 226 (27.6)
NRTIs plus NNRTI, n (%) 397 (48.5)
Adherence to HAART (n = 543), n (%)† 487 (90%)
Lipodystrophy (n = 727), n (%) 280 (38.5)
Metabolic syndrome, n (%) 169 (20.6)
Overall n = 819; HAART, highly active antiretroviral therapy; NRTIs, 
nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; NNRTI, 
non-nucleoside reverse transcriptase inhibitor; *, patients who consumed 
illicit drugs but no longer do it; †adherence, corresponding to taking ≥ 95% of 
the total pill burden prescribed in the previous week.
Table 1 – Demographic, epidemiologic, clinical, and social 
data 
WHAT SHOULD WE KNOW ABOUT METABOLIC SYNDROME AND LIPODYSTROPHY IN AIDS?
73Rev Assoc Med Bras 2012; 58(1):70-75
among patients receiving HAART; 58 (23.3%) out of 249 
patients with LD-HIV also had MS, while a half of 
116 patients with MS had concomitant LD-HIV diag-
nosis. Isolated lipoatrophy (45%) was the most frequent 
pattern observed among patients with LD-HIV, followed 
by a mixed pattern (42.9%) and isolated lipohyperthro-
phy (12.1%).
The multiple logistic regression model in-
cluded CD4 cell count, duration of antiretrovi-
ral therapy, age, and BMI as explanatory variables 
(Table 3). For every 10 years increase in age and every 
100 cells/mm3 increment in CD4 cell count, the risk for a 
diagnosis of MS increases by 80% and 10%, respectively. 
The risk of MS increased 1% for every 10 months in-
crease during antiretroviral exposure. Likewise, the risk 
of having a diagnosis of MS increased 27% for every gain 
of 1 kg/m2 in BMI. 
DISCUSSION
We found a high prevalence of MS (20.6%) in the present 
study population of HIV-infected patients followed at a 
large outpatient unit in Rio de Janeiro. This figure is simi-
lar to the prevalence of MS found in a study that enrolled 
patients under HAART from seven Latin American coun-
tries (20.2%)14, in a large cross-sectional Italian study per-
formed by Bonfanti et al.(20.6%)15 and to the data reported 
by Mondy et al.16 from an urban, Midwestern outpatient 
United States (US) population (25.5%). In a Brazilian co-
hort from Paraná, a study carried out by Diehl et al.1, the 
prevalences of LD-HIV and MS were found to be 55% and 
36%, respectively. These higher prevalences, when com-
pared to the present study, are probably due to their higher 
proportion of patients receiving HAART (87%) and their 
longer exposure to antiretroviral therapy (77 months). 
Both these factors have been broadly recognized as as-
sociated with LD-HIV9,17. There is, however, controversy 
in the literature concerning the importance of HIV treat-
ment-associated factors in the development of MS. Some 
studies14,18,19, including the present one, have found that 
the duration of antiretroviral exposure is significantly as-
sociated with MS, while others found no such an associa-
tion15,16. We believe that these conflicting results are due to 
population heterogeneity regarding genetic factors as well 
as different behavior characteristics, such as diet, physical 
activity, alcohol consumption and smoking. 
Few studies on the prevalence of MS in the gener-
al Brazilian population are available. Our age estimate 
risk for MS is very similar to that reported from a large 
and longitudinal Latin American multicenter study 
(OR: 1.05 per year)20. A population-based study con-
  Metabolic syndrome
Variables No (n = 650) Yes (n = 169) p-value∞
Age* 40 (± 10) 46 (± 10) < 0.001
BMI* 23 (± 3.7) 27 (± 5) < 0.001
Duration of antiretroviral therapy (mo)* 52 (± 37) 63 (± 39) 0.003
Receiving PI 184 (28%) 40 (24%) NS
Adherence to antiretroviral therapy† 379 (88%)‡ 108 (95%)§ 0.05
CD4 cell count (cells/mm3)* 370 (± 216) 455 (± 284) < 0.0001
Viral load (log/mL)* 3.2 (± 1.3) 3 (±1.2) NS
Lipodystrophy**(n = 721) 219 (38%)¶ 61 (42.4%)£ NS
*mean (±SD); mo, month; †Adherence, corresponding to taking ≥ 95% of the total pill burden prescribed in the previous week; ‡out of 
429 patients; §out of 114 patients; ∞t-test p-value; ¶out of 577 patients; £out of 144 patients; **(n = 721), 721 patients were screened for 
lipodystrophy.
Table 2 – Differences between HIV-infected patients receiving antiretrovirals with and without metabolic syndrome
Variables Univariate analysis Multivariate analysis
  OR (95% CI) p OR (95% CI) p
Ageį 1.07 (1.04, 1.09) < 0.001 1.08 (1.05, 1.1) < 0.001
CD4 cell countį 1.001 (1.001, 1.002) < 0.001 1.001 (1.0001, 1.002) 0.02
BMIį 1.22 (1.2, 1.3) < 0.001 1.27 (1.2, 1.4) < 0.001
Duration of ARV¶į 1.008 (1.003, 1.014) 0.01 1.001 (1.001, 1.02) 0.03
įcontinuous variable; ¶month; BMI, body mass index, OR, odds ratio; 95%CI, 95% conﬁdence interval; ARV, antiretroviral therapy. Hosmer and 
Lemeshow Test = 2.963, p value = 0.94
Table 3 – Risk factors for metabolic syndrome
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ducted in Vitória found a prevalence of MS of 29,8% 
in general population. Prevalence increased from the 
youngest (26-34 years) to the oldest (55-64 years) age 
groups (15.8% and 48.3%, respectively)21. The BMI is a 
traditional risk factor for MS, and our results corrobo-
rate to this assertive, because the prevalence of MS aug-
mented among overweight (≥  25  kg/m2) patients as it 
was also observed in other Brazilian studies1, 21 and else-
where16.
In our study, patients with MS were more likely to 
have greater CD4 cell counts. Similar findings were re-
ported by an American study16 where mean CD4 cell 
count was significantly higher in patients with MS when 
compared to patients without MS (542 cells/mm3 vs. 
417 cells/mm3). 
We and others1,18 have found that a low HDL-cho-
lesterol is the most common metabolic abnormality, 
followed by hypertriglyceridemia. Otherwise, a Bra-
zilian population-based study conducted by Salaroli 
et al.16 found that the most frequent component of the 
MS in males was arterial hypertension, followed by 
hypertriglyceridemia, low HDL-cholesterol, hypergly-
cemia and increased waist circumference, whereas low 
HDL-cholesterol, increased waist circumference, hy-
pertriglyceridemia and hyperglycemia were the most 
frequent in females. In contrast to our findings, another 
Brazilian study carried out in São Paulo22 found that the 
most prevalent components were, in order of frequency, 
hypertriglyceridemia, increased waist circumference, 
hyperglycemia, low HDL-cholesterol and hypertension.
As the HIV-infected population grows older, MS 
will likely become increasingly prevalent4. Some au-
thors found 81%16 and 88%22 of HIV-infected patients 
with at least one of the individual components of MS. 
These estimates were very consistent with our find-
ings. Cardiovascular risk factors were highly prevalent 
in our study population. Our findings were very conso-
nant with those of Silva et al.22, who found 27% and 18% 
prevalences of smoking and hypertension, respectively. 
The striking prevalence of familiar history of cardiovas-
cular disease verified among our patients was also con-
sistent with 40%22 and 31%14 previously reported in the 
literature.
It is also remarkable the difference on prevalences 
of MS observed between the studies of Diehl et al.1 and 
ours (36% vs. 20%). It might be explained by the higher 
proportion of patients with an isolated or combined hy-
pertrophy pattern of LD-HIV observed in their study. 
Under these circumstances, the increased abdominal 
girth, visceral adiposity and its associated metabolic dis-
turbances are more prevalent, and it could have added to 
the emergence of surplus cases of MS seen in their study.
Studies on MS among Brazilian HIV-infected patients 
are scarce as well as on its association with LD-HIV. In our 
research and in the study by Diehl et al.1, the patients with 
MS did not significantly meet consensus criteria for both 
metabolic syndrome and LD-HIV. In contrast, Carr et al.23 
found a statistical association between MS and LD-HIV. 
Potential explanations for discrepant results observed be-
tween those studies could be the employment of a more 
accurate method for diagnosing LD-HIV developed by 
Carr et al.23, besides demographic differences verified be-
tween those study samples. 
Concerning the association between MS and LD-HIV, 
we know that a loss of peripheral fat occurs in the latter 
syndrome that leads to a lessened ability for storing fat 
in peripheral adipocytes. In consequence, the dietary 
fat will be deposited in the abdominal adipocyte, but, due 
to their smaller capacity to store fat, fatty-acids released 
into intra-abdominal-visceral region return to circulation 
through portal vein and deposit first in liver (causing ste-
atosis and insulin resistance) and also in muscle and pan-
creas. This is defined as ectopic fat deposition theory9,10. 
The MS has a multifactorial etiology; the emergence of 
this syndrome may not indicate a single underlying patho-
logical process. Genetic background, HIV infection by it-
self, abnormal release of adipokines or antiretroviral-relat-
ed effects may be partially responsible for some elements 
of this mixed syndrome9,19. In our study, we observed an 
increased risk for MS in the sample patients as they in-
creased their age, BMI, CD4 cell counts and exposure to 
antiretrovirals, corroborating with other studies1,24. The 
BMI was the variable with greater OR in our MS regres-
sion model and together with CD4 cell counts represented 
the health return of these patients promoted by antiretro-
viral therapy. Antiretrovirals, in turn, administered over 
an extended period of time, play a vital role in prolonging 
the lifespan of HIV-infected patients2. However, its chron-
ic metabolic consequences on lipids became prevalent in 
the clinical practice25 and contributed for the development 
of MS in our study.
This panel demonstrates how physicians that care for 
HIV-infected patients are constantly facing new chal-
lenges. And in this changing scenario, physicians need to 
determine to what extent this represents a restoration of 
health or an increase in cardiovascular risk factors.
CONCLUSION
In conclusion, we found that traditional risk factors for 
cardiovascular disease, such as older age and increased 
body mass index, as well as factors inherently associated 
with HIV infection, such as an increased CD4 cell count 
and a longer exposure to antiretroviral therapy, seem to 
be associated with the metabolic syndrome in the present 
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study population. Furthermore, the current obesity, seden-
tary lifestyle, dyslipidemia, and hypertension “epidemics”, 
besides smoking, alcohol consumption and type 2 diabetes 
mellitus, also target the HIV-infected population. 
As of regular medical appointments, physicians shall 
not lose the opportunity to encourage patients to change 
lifestyle and unhealthy social habits, choose individual 
antiretroviral regimens that combine the least toxic with 
greater antiviral activity, and decide if a hypolipemic 
agent is needed. The interdisciplinary assistance, includ-
ing psychological, nutritional and other related-medical 
specialties, should be considered and may be of utmost 
importance.
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